'Regenerative Medicine Market Will Reach $1.4 Billion in 2012' States Visiongain Report

'Regenerative Medicine Market Will Reach $1.4 Billion in 2012' States Visiongain Report PR Newswire LONDON, September 11, 2012 LONDON, September 11, 2012 /PRNewswire/ -- A new report by visiongain predicts that the overall world market for translational regenerative medicine will reach $1.4bn in 2012. That revenue forecast and others appear in Translational Regenerative Medicine Market Prospects 2012-2022, published in September 2012. Visiongain is a business information provider based in London, UK. Visiongain forecasts that the overall regenerative medicine market will multiply in size from 2012 to 2022. The regenerative medicine industry is in its infancy; however marketed products have achieved commercial success. Visiongain believes the strength of the regenerative medicine market is its potential to treat a plethora of diseases. Growth of the market will be driven by targeting serious, prevalent disorders such as cancer, cardiovascular disease and diabetes. In these areas, the potential for regenerative medicine technologies is vast, and regulatory and cultural uncertainties about the field will not derail its progress from 2012 to 2022. Dr Peter Williamson, a pharmaceutical industry analyst in visiongain, said: "Regenerative medicine is a market with huge potential. The key to its future lies in the successful approval and commercialisation of new products.